FORMULATION, DEVELOPMENT AND EVALUATION OF BILAYER TABLETS OF ANTIHYPERTENSIVE DRUGS
Debashree Ray, Nilesh Jain, R.B. Goswami
ABSTRACT
Hypertension is a chronic, frequently asymptomatic medical condition characterised by increased systemic arterial blood pressure. The bi-layer tablet heralds a new era in the and with a variety of features to ensure effective medication delivery. Thus, this study aims at developing & evaluating bilayer tablet of antihypertensive drugs. The formulation & evaluation of bilayer tablet was performed according to standard method. The results of pre-compressional parameters of Hydrochlorothiazide instant release tablets suggested that all parameters are within the range. The drug content was found to be maximum for 99.45±0.32 % in IF7 formulation. The disintegration time was observed to be lowest for 43±2. Result of pre-compression properties of gastroretentive layer of Captopril tablets were also within the limits. Results of post compression properties of Captopril tablets varied suggested that the % drug content was observed to be maximum for F7 which is 99.45±0.19 % .The In-vitro drug release study of tablets suggest that the formulation F7 shows 99.12 % Cumulative Drug Release in 12 hours. Further IF7 formulation & F7 formulation was combined to produce a bilayer tablet. For this complete bilayer tablet the Hardness & friability was observed to be 6.5 kg/cm2& 0.754% respectively. The thickness of tablet was calculated as 5.23mm. The weight variation test was also passed by this tablet successfully. Additionally the drug content of in house bi layer tablet was checked. The results revealed that the bilayer tablet contain 99.45 of Hydrochlorothiazide & 99.12 % of captopril. The Dissolution rate studies of bilayer tablets further clarified that at 12 hr the % Drug Release for captopril was found to be 99.45%. The Instant layer of Hydrochlorothiazide release approx 98.85 percent drug within 1.5 Hrs. Thus, from results it can be inferred that stable dosage form for Hydrochlorothiazide as immediate and captopril as sustained release via bilayered tablets can be produced.
[Full Text Article]